Pneumagen is developing a glycan targeted intranasally delivered therapy for the pan-viral, universal treatment of infectious diseases of the respiratory tract
Latest news
21 Jan, 2021
Pneumagen Announces £2.5m fundraising to advance universal treatment for viral respiratory infections into the clinic this year
05 Oct, 2020
Pneumagen’s Neumifil for combating COVID-19 featured in SCRIP’s 10 to watch at BIO-Europe Digital
16 Sep, 2020
Pneumagen Announces Scientific Advisory Board and Development Team Appointments
Meet the team
Douglas Thomson
Chief Executive Officer
Dr David Howat
Development Director
Thomas Engelen
Non-executive Chairman
Professor Garry Taylor
Director and Chairman of the Scientific Advisory Board
Mark R. Bamforth
Non-executive Director